Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
Lantern Pharma Inc. (NASDAQ:LTRN), a leading artificial intelligence (AI) company in the field of cancer therapy development, is set to present at the upcoming ThinkEquity Conference on October 19, 2023. The conference, to be held at the Mandarin Oriental in New York, NY, will provide Lantern Pharma with an opportunity to showcase its groundbreaking AI and machine learning (ML) platform, RADR®, and its multiple clinical stage drug programs.
The presentation by Lantern Pharma’s management is scheduled for 1:30 p.m. ET on October 19. In addition to the presentation, the company’s management will also be available for one-on-one meetings throughout the conference, allowing for further discussions and collaborations.
Lantern Pharma is revolutionizing the world of oncology drug discovery and development by leveraging the power of AI and ML. Its proprietary RADR® platform utilizes over 34 billion oncology-focused data points and a library of more than 200 advanced ML algorithms. This cutting-edge technology enables Lantern Pharma to address real-world challenges in oncology drug development, significantly reducing costs, accelerating timelines, and ultimately transforming the lives of cancer patients.
With the guidance of world-class scientific advisors and collaborators, Lantern Pharma has successfully advanced its pipeline of therapies, including eleven cancer indications and an antibody-drug conjugate (ADC) program. Remarkably, the company has achieved an average timeline of 2-3 years from initial AI insights to first-in-human clinical trials, with a cost range of $1.0-2.0 million per program. Such efficiency and cost-effectiveness are unprecedented in the industry.
Among Lantern Pharma’s lead development programs is a Phase 2 clinical trial for a promising product candidate. Additionally, the company has recently initiated Phase 1 clinical programs for two other lead product candidates with potential applications in multiple important cancer indications. Recognizing the urgent need for effective treatments for CNS and brain cancers, Lantern Pharma has also established a wholly-owned subsidiary, Starlight Therapeutics Inc., dedicated to advancing therapies in this area.
The potential impact of Lantern Pharma’s AI-driven pipeline is immense, with an estimated combined annual market potential exceeding $15 billion USD. These innovative product candidates have the potential to provide life-changing therapies to hundreds of thousands of cancer patients worldwide.
To stay updated on Lantern Pharma’s progress and developments, interested individuals can visit the company’s website at www.lanternpharma.com. The company also maintains an active presence on LinkedIn and Twitter (@lanternpharma), providing valuable insights and updates to its followers. Additionally, readers can sign up for the company’s newsletter, “The Spark,” to receive regular updates directly.
It is important to note that this press release contains forward-looking statements, reflecting Lantern Pharma’s expectations and plans for the future. While these statements are based on the company’s current beliefs and assumptions, there are inherent risks and uncertainties that could cause actual results to differ materially. Factors such as the success of research efforts, regulatory approvals, and market conditions can impact the realization of these forward-looking statements. Lantern Pharma encourages investors to refer to its Annual Report on Form 10-K for a comprehensive understanding of the risks involved.
In conclusion, Lantern Pharma’s participation in the ThinkEquity Conference highlights its commitment to advancing cancer therapy development through the power of AI and ML. With its RADR® platform and growing pipeline of innovative product candidates, the company is poised to make a significant impact in the field of oncology. By leveraging cutting-edge technology, Lantern Pharma aims to provide hope and improved outcomes for cancer patients worldwide.